Clinical Trial Detail

NCT ID NCT01089101
Title Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors National Cancer Institute (NCI)
Indications

malignant glioma

optic nerve glioma

pilocytic astrocytoma

Therapies

Selumetinib

Age Groups: adult child

Additional content available in CKB BOOST